Immunotherapy and emerging targets in phase 3
EASL LiverTree™, Sandrine Faivre, 210753
EASL-EASD Symposium: Testing strategies and pathways in NAFLD: Panel Discussion
EASL LiverTree™, Session Speakers, 212772
The Cardiologist perspective
EASL LiverTree™, Christopher D. Byrne, 210741
The road ahead – will novel HBV treatments enter clinics soon? Immunological therapies
EASL LiverTree™, Mala Maini, 210757
Revised 2018 WHO Guidelines for the care and treatment of persons with chronic HCV
EASL LiverTree™, Dr. Marc Bulterys & Dr. Saeed Sadiq Hamid, 214370
The General Practicionner perspective
EASL LiverTree™, Rachel Pryke, 210740
Systemic therapy: Current status and lessons learned from success and failure
EASL LiverTree™, Maria Reig, 210752
Clinicians as key partners in meeting the 2030 elimination goals
EASL LiverTree™, Rakesh Aggarwal, 210746
Stopping NUC therapy before HBsAg loss – a good idea?
EASL LiverTree™, Florian van Boemmel, 210756
Ablation and transarterial approaches. Efficacy vs benefit
EASL LiverTree™, Jens Ricke, 210751
Fighting HBV with limited resources: The global perspective
EASL LiverTree™, Maud Lemoine, 210755
EASL-EASD Symposium: Testing strategies and pathways in NAFLD: Chair
EASL LiverTree™, Laurent Castera, 210736
The Hepatologist perspective
EASL LiverTree™, Lawrence Serfaty, 210738
Monitoring progress towards the elimination of viral hepatitis
EASL LiverTree™, Yvan Hutin, 210744
Short review of unmet needs in HCC treatment
EASL LiverTree™, Jordi Bruix, 210750
Introduction: Aims and open questions in HBV management
EASL LiverTree™, Jörg Petersen, 210754
EASL-WHO symposium: Meeting the 2030 elimination goals of the WHO viral hepatitis strategy: Introduction
EASL LiverTree™, Prof. Tom Hemming Karlsen & Gottfried Hirnschall, 214368
Quantifying the Impact of Achieving the World Health Organization (WHO) Global Health Sector Strategy (GHSS) Goals for Hepatitis C in the EURO Region
EASL LiverTree™, Sarah Blanch, 206383
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the 'underwater portion of the iceberg' matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries?
EASL LiverTree™, Sarah Blach, 206385
Bile duct organogenesis using ECM micropatterning
EASL LiverTree™, Mazari-Arrighi Elsa, 206943
Comparing the prevention gains of different treatment strategies at the global, regional, and country level: a modelling study
EASL LiverTree™, Adam Trickey, 206444
Selective NDRP1 E3 ubiquitin ligase overexpression in inflammatory macrophages using functionalized carbon nanoparticles promotes fibrosis regression in cirrhotic mice
EASL LiverTree™, Pedro Melgar-Lesmes, 206894
Preliminary efficacy and safety of acetyl-CoA carboxylase (ACC) inhibitor GS-0976 in patients with compensated cirrhosis due to NASH
EASL LiverTree™, Mazen Noureddin, 207296
Development and characterization of unique Hepatitis C virus neutralizing antibodies associated with infection outcome
EASL LiverTree™, Shiri Elmedvi Baran, 207745
Interim evaluation and projected impact of the hepatitis C virus elimination program in Georgia
EASL LiverTree™, Aaron Lim, 206373
Nurse-led Clinic for Liver Cirrhotic Patients: Effects on Health Related Quality of Life
EASL LiverTree™, Maria Hjorth, 206837
Effects of a PEGylated fibroblast growth factor 21 variant on steatosis, inflammation, and fibrosis in a mouse model of non-alcoholic steatohepatitis
EASL LiverTree™, Bradley Zinker, 206886
A pan-genotype HCV T cell vaccine, in a simian adenovirus vector, to target T cell epitopes conserved across multiple HCV genotypes
EASL LiverTree™, Timothy Donnison, 207749
Scale-up of the national HCV screening and treatment program in Indonesia: data from Jakarta, West Java and Central Java
EASL LiverTree™, Jilian Sacks, 206400
Human amnion epithelial cells reduce liver fibrosis via effects on macrophages phenotype and liver progenitor cells in murine liver injury
EASL LiverTree™, Majid Alhomrani, 206902
Effet of bariatric surgery in biopsy-proven NASH patients after 5 years
EASL LiverTree™, Guillaume Lassailly, 207293
Seeking genetic determinants of resistance to hepatitis C virus infection in a highly resistant cohort
EASL LiverTree™, Daniel Felmlee, 207669
The impact of EMR modification and a multi-disciplinary care team on the hepatitis C care cascade of a US Federally Qualified Health Center
EASL LiverTree™, Lora Magaldi, 206405
Human skin-derived precusor cells: a potential source for cellular therapy of the liver
EASL LiverTree™, Joery De Kock, 206941
Statin inhibits HDV assembly, secretion, and large hepatitis delta antigen-Smad3-Twist mediated epithelial-mesenchymal transition
EASL LiverTree™, Jaw-Ching Wu, 207683
Multidisciplinary intervention on lifestyle improves the management of patients with nonalcoholic fatty liver disease
EASL LiverTree™, Sara POLICARPO, 207795
Evaluation of the Xpert Fingerstick HCV Viral Load assay
EASL LiverTree™, François Lamoury, 206419
Liver biopsy derived induced pluripotent stem cells provide unlimited supply for the generation of hepatocyte-like cells.
EASL LiverTree™, Diego Calabrese, 206938
Molecular diversity of HDV strains that spread in France: a study of 2224 clinical strains prospectively collected during fifteen years
EASL LiverTree™, Athenaïs Gerber, 207711
Clinical Outcomes in biopsy-proven NAFLD Patients from the HEPAmet Spanish Registry.
EASL LiverTree™, Javier Ampuero, 207817
High agreement with HCV RNA in screening and DAA treatment monitoring indicates that cost-effective HCV core Ag test can also be enlisted in the fight to eliminate hepatitis C 
EASL LiverTree™, Nazibrola Chitadze, 206436
Differentiation of human pluripotent stem cells into hepatocytes is more efficient in spheroids than in 2D culture
EASL LiverTree™, Messina Antonietta, 206935
Cytokine-Dependent Activation of MAIT Cells by the TLR8 agonist GS-9688 but not the TLR7 Agonist GS-9620
EASL LiverTree™, Hassan Javanbakht, 207747
A mobile application for the management and follow-up of patients with Non-Alcoholic Fatty Liver Disease
EASL LiverTree™, Roberta Forlano, 207785
Eradicate Hepatitis C:  a pilot of treatment as prevention in active drug users
EASL LiverTree™, Jasmine Schulkind, 206389
Generation of a unique liver progenitor cell gene signature to identify LPCs and LPC activation in chronic liver diseases
EASL LiverTree™, Stefaan Verhulst, 206931
A novel chimpanzee adenoviral vectored HBV vaccine, encoding multiple HBV antigens with a shark invariant chain adjuvant, for use in HBV immunotherapy
EASL LiverTree™, Senthil Chinnakannan, 207725
NAFLD/NASH patients with compensated cirrhosis (CC) had a high prevalence of comorbidities, substantial liver disease progression, and increased annual number of hospitalizations and associated costs in France: a PMSI database analysis
EASL LiverTree™, Jérôme Boursier, 207788
Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with Sofosbuvir-based regimens
EASL LiverTree™, Alessandra Mangia, 210732
A phase 1/2, randomized, placebo controlled and open label extension studies of Givosiran and investigational RNA interference therapeutic, in patients with acute intermittent porphyria
EASL LiverTree™, Eliane Sardh, 210730
Award ceremony 2
EASL LiverTree™, Session Speakers, 210729
Primary spontaneous bacterial peritonitis prophylaxis is associated with greater ICU admission and 30-day mortality compared to secondary spontaneous bacterial peritonitis prophylaxis
EASL LiverTree™, Jasmohan S Bajaj, 210728
NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks
EASL LiverTree™, Stephen Harrison, 210727
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis c: the Navigator-II study
EASL LiverTree™, Roberta D'Ambrosio, 210726
Novel characterization of the gut microbiome in patients with NASH and longitudinal changes associated with histological improvement
EASL LiverTree™, Rohit Loomba, 207337
Secreted ectodomain of SIGLEC-9 and MCP-1 ameliorate acute liver failure in rats by altering bone marrow macrophage polarity
EASL LiverTree™, Takanori Ito, 207354
Elevated programmed death ligand 2 (PDL2) in macrophages of BALB/c mice model of liver fibrosis associated with decreased CD80 and IL12 expressions 
EASL LiverTree™, Johnny Amer, 207355
Impact of acute hepatic porphyrias on quality of life and work loss: an analysis of EXPLORE natural history study
EASL LiverTree™, Sonalee Agarwal, 207372
Trends in healthcare utilization in the United States and Europe associated with patient with acute hepatic porphyria with recurrent attacks in EXPLORE: a prospective, multinational natural history study of patients with acute hepatic porphyria
EASL LiverTree™, Sonalee Agarwal, 207373
The Galactose Elimination Capacity test may monitor treatment response and disease progression in patients with Wilson Disease
EASL LiverTree™, Thomas Damgaard Sandahl, 207390
The global prevalence of lysosomal acid lipase deficiency estimated by meta-analysis of pathogenic mutations and functional variants from next-generation sequencing data
EASL LiverTree™, Anna Carter, 207391
Soluble serum vascular adhesion protein (sVAP)-1: a new biomarker in primary sclerosing cholangitis?
EASL LiverTree™, Francesca Saffioti, 207409
Comparison of twelve noninvasive liver reserve models in HCC patients undergoing resection  
EASL LiverTree™, SHU YEIN HO, 207410
Platelet and spleen volume criteria exclude more oesophageal varices needing treatment than Baveno VI criteria with 100% sensitivity
EASL LiverTree™, Christina Levick, 207426
Overestimation and underestimation of liver fibrosis stage classification assessed by transient elastography and two-dimensional shear wave ultrasound
EASL LiverTree™, sang gyune kim, 207427
Distinct functions of phosphorylated and un-phosphorylated STAT1 in hepatocellular carcinoma
EASL LiverTree™, Buyun Ma, 207448
High fat diet induces a tumor like metabolism in the liver
EASL LiverTree™, joao duarte, 207449
Therapeutics of cell-specific MAPK modulation in chronic liver disease using (siJNK2) nanodelivery
EASL LiverTree™, Marius Maximilian Woitok, 207465
Deletion of MyD88 in non-parenchymal cells, but not in parenchymal cells attenuates the progression of hepatocellular carcinoma
EASL LiverTree™, Antje Mohs, 207466
Functional genomics identified actin cytoskeleton remodeling required for the hypoxia-mediated EMT: a mechanistic link of tumor size to metastasis
EASL LiverTree™, Sen-Yung Hsieh, 207484
The HDAC inhibitorbelinostat enhances the anti-tumor efficacy of immune checkpoint inhibitors ina murine hepatocellular carcinoma model
EASL LiverTree™, Pablo Sarobe, 207485
A new insight on the stem cell growth factor beta as astrong predictor of therapy response in hepatocellular carcinoma
EASL LiverTree™, Riccardo Patti, 207502
Disrupted cholesterol synthesis leads to female prevalent hepatocellular carcinoma in transgenic mice
EASL LiverTree™, Kaja Blagotinšek Cokan, 207503
Assessing Baveno VI criteria with a new point-shear wave elastography technique: the BAVElastPQ study
EASL LiverTree™, Giulia Gibiino, 207520
The efficacy and clinical outcome of transjugular intrahepatic portosystemic shunts (TIPS) in the management of ectopic variceal bleeding: a multicenter retrospective study
EASL LiverTree™, Rosalie Oey, 207521
THE AMELIORATION OF MUSCLE WASTING LEADS TO THE IMPROVEMENT OF COGNITIVE IMPAIRMENT AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT: A PROOF OF CONCEPT THAT SARCOPENIA AND HEPATIC ENCEPHALOPATHY ARE CAUSALLY RELATED
EASL LiverTree™, Stefania Gioia, 207537
NON CIRRHOTIC PORTAL HYPERTENSION SECONDARY TO OXALIPLATIN THERAPY : INCIDENCE AND PRESENTATION 
EASL LiverTree™, Stefania Gioia, 207538
Men have higher mortality in cirrhosis: outcomes by gender and etiology in a large, diverse cohort
EASL LiverTree™, Apurva Yeluru, 207553
Prior or On-treatment Infection Does Not Affect Response to Treatment or Survival in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
EASL LiverTree™, Florence Wong, 207554
Predictors of Endoscopic High Risk EsophagealVarices in Compensated Cirrhosis: Can we Avoid Fibroscan?
EASL LiverTree™, Julian Hercun, 207570
Second-look endoscopy and prolonged use of proton pump inhibitor and octreotide after variceal ligation reduce early bleeding rate in cirrhosis with large gastroesophageal varices: a single-blinded, single-centered and randomized controlled trial
EASL LiverTree™, Anjiang Wang, 207572
Dynamic Visual Processing in Patients with Decompensated Cirrhosis
EASL LiverTree™, Katherine Wong, 207589
The physical component of the SF-36 Quality of Life tool is an independent predictor of mortality in patients with severe ascites
EASL LiverTree™, Stewart Macdonald, 207590
Combined elastin and collagen proportionate area (ECPA) sub-classifies cirrhosis and predicts clinical outcomes
EASL LiverTree™, Avik Majumdar, 207606
Transjugular Intrahepatic Portosystemic Shunt (TIPS) is highly effective in patients with a MELD score < 20 and does not require routine Doppler ultrasound follow-up
EASL LiverTree™, Koos de Wit, 207607
Four years outcomes of Baveno VI low risk cirrhotic patients
EASL LiverTree™, Priscila Pollo Flores, 207624
A novel sonographic parameter for the quantification of muscle mass in cirrhosis
EASL LiverTree™, Kazufumi Kobayashi, 207625
Drug-induced encephalopathy in cirrhotic patients with neurological symptoms: a metabolomic study.
EASL LiverTree™, Nicolas Weiss, 207640
Endoscopic radiofrequency ablation for the treatment of gastric antral vascular ectasia in cirrhotic patients: a bi-centric clinical and economical cost-effective analysis
EASL LiverTree™, Marco Senzolo, 207641
Longitudinal analysis of HCV full genomes in patients failing NS5A inhibitors reveals the selection of novel amino acid substitutions outside NS5A
EASL LiverTree™, Slim Fourati, 207659
NLRX1 and the p.Arg707Cys Variant in NLRX1 Affect Host Susceptibility of Hepatitis B Virus Infection in Huh7-NTCP cells
EASL LiverTree™, Liang Peng, 207661
Identification of HBV genotypes and mutations associated to antiviral resistance and vaccine escape in serum and oral fluid samples from chronic hepatitis B patients
EASL LiverTree™, Moyra Machado Portilho, 207678
Identification of a stable HBV inter-genotype (A/G) recombinant strain in a guinean patient in 'grey zone' of treatment
EASL LiverTree™, Ana Isabel Gil, 207679
Proteomic analysis of hepatitis B virus cccDNA-specific associated proteins identifies crucial regulators of viral transcription and RNA processing
EASL LiverTree™, Barbara Testoni, 207694
Deep sequencing analysis highlights variations associated with HBeAg seroconversion in adolescents with chronic hepatitis B
EASL LiverTree™, Christophe Combet, 207713
Hepatitis B virus entry in primary human hepatocytes initiates toll-like receptor 2-dependent immune signaling.
EASL LiverTree™, Ruth Broering, 207732
Ex vivo characterization of co-inhibitory molecules on MHC class II tetramer positive HCV-specific CD4+ T cells in HCV infection
EASL LiverTree™, Christin Ackermann, 207751
Lipofuscin is detected in early  stages of the disease in liver biopsies of patients with Non-Alcoholic Fatty Liver Disease
EASL LiverTree™, Roberta Forlano, 207786
The effect of microvascular complications of diabetes on advanced fibrosis in nonalcoholic fatty liver disease
EASL LiverTree™, Russell Rosenblatt, 207803
Predisposition to diabetes is related to insulin resistance in NAFLD patients and to decreased insulin secretion in HCV patients.
EASL LiverTree™, Amalia Gastaldelli, 207820

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings